https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49803 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.]]> Wed 31 May 2023 15:59:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51575 Wed 29 May 2024 15:12:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48348 Wed 28 Aug 2024 09:55:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39575 Wed 27 Jul 2022 14:43:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45246 Wed 26 Oct 2022 15:22:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38068 p <0.001), longer disease duration (HR=1.01, p=0.038), a higher Expanded Disability Status Scale score (HR=1.30, p<0.001), more rapid disability trajectory (HR=2.82, p<0.001) and greater number of relapses in the previous year (HR=1.07, p=0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR=0.62, p=0.039) and disease-modifying therapy exposure (HR=0.71, p=0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. Conclusion:Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.]]> Wed 24 May 2023 12:22:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36699 Wed 24 Jun 2020 18:21:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38853 r = 0.3–0.5; P ≤ 0.05). Total ARCS predicts cognitive impairment with good sensitivity and specificity relative to the BICAMS tests (AUC = 0.8; P = 0.00045). Total ARCS detects higher levels of impairment than BICAMS in MS patients (44% versus 21%). The memory domain of the ARCS and the BVMT-R were the best predictors of employment status (OR = 1.12 and 1.14, P  < 0.05). Conclusion: BICAMS and ARCS have comparable sensitivity for cognitive impairment in MS. Memory assessment from either tests is the best predictor of employment status; however, the BICAMS is a better predictor of work productivity.]]> Wed 23 Nov 2022 15:41:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38878 n = 13) erythrocyte-derived (CD235a) extracellular particles were increased, while platelet-derived (CD41b), leukocyte-derived (CD45), and CD4⁺T cell-derived (CD4) extracellular particles were decreased compared to both healthy controls (n = 27) (p<0.05) and secondary progressive multiple sclerosis patients (n = 9) (p < 0.05). Endothelium-derived extracellular particles (CD146) were increased in stable relapsing-remitting multiple sclerosis patients (n = 17) compared to healthy controls (p < 0.05). Extracellular particles from several different cells of origin correlated with each other and clinical parameters (e.g. disease duration, number of relapses, EDSS), though clinical correlations did not withstand corrections for multiple comparisons. Conclusions: Concentrations of erythrocyte-, leukocyte-, and platelet-derived extracellular particles were altered in relapsing multiple sclerosis patients and endothelium-derived extracellular particles were increased in stable relapsing-remitting patients compared to healthy controls. Extracellular particles may provide insights into altered the crosstalk between peripheral blood cells in multiple sclerosis, which may lead to the discovery of novel therapeutic targets.]]> Wed 23 Feb 2022 11:05:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51433 Wed 22 May 2024 15:28:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39262 Wed 22 Jun 2022 19:13:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54397 Wed 21 Feb 2024 15:48:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54877 Wed 20 Mar 2024 13:18:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51652 Wed 13 Sep 2023 10:00:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52621 Wed 13 Mar 2024 14:21:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38205 2 = 0.0%; p=0.5). Conclusion: Although the CVS is a clinically relevant and viable sign, further work is needed to integrate this into the existing diagnostic criteria. As manual determination is a time-consuming process, the development of automated methods will be beneficial. With improvements in computational imaging techniques, the CVS will have an important role in the diagnosis and differentiation of MS.]]> Wed 11 Aug 2021 12:11:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39516 Wed 10 Aug 2022 11:31:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49147 Wed 07 Feb 2024 15:06:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53604 75% (AUC = 0.79, SE = 0.014). Discrimination between ISO lesions and cNAWM was accomplished with an accuracy of >69% (AUC = 0.74, SE = 0.018), while discrimination between BH lesions and cNAWM was achieved at an accuracy of >80% (AUC = 0.87, SE = 0.021). Conclusions: Our results highlight the potential of APTw imaging for use as a non-invasive technique that is able to provide essential molecular information to clinicians and researchers so that the stages of inflammation and degeneration in MS lesions can be better characterized.]]> Wed 07 Feb 2024 14:34:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49100 Wed 06 Mar 2024 15:23:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36092 Chlamydophila pneumoniae (Cpn). The objective of the current study is to determine the effect of a combined antibiotic protocol (CAP) on the venous flow in MS patients as measured by a quantitative duplex ultrasound examination (QDUS). Method: A non-randomised before-after cohort study was conducted to investigate differences in blood flow volumes pre and 6-months post antibiotic treatment for Cpn infection. Flow volume data were measured by QDUS across affected and unaffected sides from multiple veins segments, including internal jugular vein (IJV) segments J2 and J3, and vertebral vein (VV), as well as global arterial blood flow (GABF). Results: 91 patients were included in the study. 64 (70%) were found to have positive Cpn serology. There was a statistically significant post-treatment difference seen for the affected side of Cpn infected patients (mean difference = 56 mL/min, p = 0.02). There was a non-significant increase seen for the affected side of uninfected patients (mean difference = 23 mL/min, p = 0.2). The difference in these effects (34 mL/min) was not statistically significant (p = 0.3). The mean flow rate decreased in the unaffected side for both infected (-27 mL/min, p = 0.5) and uninfected patients (-69 mL/min, p = 0.01). There was a statistically significant post-treatment increase in GABF for the infected patients (mean difference = 90 mL/min, p = 0.02) and a difference of 76 mL/min for non-infected patients (p = 0.01). Conclusion: A CAP appears to improve the extra-cranial circulation in patients diagnosed with MS. This effect is statistically significant in patients with positive Cpn serology, although patients with negative Cpn serology also show some benefit, betraying a lack of specificity of this effect.]]> Wed 05 Feb 2020 14:51:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:56301 Wed 04 Sep 2024 11:43:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38113 Wed 04 Aug 2021 11:40:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55899 Wed 03 Jul 2024 15:33:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:47837 n = 330), annual transition probabilities were obtained between no/mild (Expanded Disability Status Scale (EDSS) levels 0-3.5), moderate (EDSS 4-6.0) and severe (EDSS 6.5-9.5) disability. Results: From no/mild disability, 6.4% (95% confidence interval (CI): 4.7-8.4) and 0.1% (0.0-0.2) progressed to moderate and severe disability annually, respectively. From moderate disability, 6.9% (1.0-11.4) improved (to no/mild state) and 2.6% (1.1-4.5) worsened. From severe disability, 0.0% improved to moderate and no/mild disability. Male sex, age at onset, longer disease duration, not using immunotherapies greater than 3 months and a history of relapse were related to higher probabilities of worsening. Conclusion: We have estimated probabilities of changing disability levels in Australians with RRMS. Probabilities differed between various subgroups, but due to small sample sizes, results should be interpreted with caution. Our findings will be helpful in predicting long-term disease outcomes and in health economic evaluations of MS.]]> Wed 01 Feb 2023 15:34:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54058 Tue 30 Jan 2024 13:55:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51272 Tue 29 Aug 2023 15:42:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50909 Tue 29 Aug 2023 11:01:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55423 Tue 28 May 2024 14:56:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39853 Tue 26 Jul 2022 10:28:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53309 .05). Compared to HCs, both RRMS cohorts showed volume changes in white matter (−13%), gray matter (−16%), and cerebral spinal fluid (CSF) (+17-23%), as well as reduced NAA (−17%, p =.001, hippocampus), (−7%, p =.001, PCG), and (−9%, p =.001, PFC). MRI/S metrics in three regions were moderately correlated with cognition and fatigue functions. Conclusion: While both treatment arms showed overall similar volumetric and neurometabolic profiles, longitudinal studies are warranted to clarify neurometabolic changes and associations with treatment efficacy.]]> Tue 21 Nov 2023 12:02:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54378 Tue 20 Feb 2024 20:24:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54334 Tue 20 Feb 2024 16:06:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54315 Tue 20 Feb 2024 14:35:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51798 Tue 19 Sep 2023 08:56:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52582 Tue 17 Oct 2023 15:55:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46354 Tue 15 Nov 2022 14:40:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44317 Tue 11 Oct 2022 16:19:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36572 Tue 09 Jun 2020 11:40:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42900 Tue 06 Sep 2022 15:14:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52120 Thu 28 Sep 2023 15:04:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45379 Thu 27 Oct 2022 15:58:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37635 65% by area and 16/50 a low grade stenosis of between 40-65% by area compared to 1/50 low grade stenoses in this segment in the controls. The commonest cause of the stenosis was a giant arachnoid granulation. The optic nerve sheaths were larger in MS than controls (p=0.0006). Comparing MS patients with transverse sinus stenosis to those without, the pituitary height was 16% smaller and BMI 25% larger (p=0.02 and 0.003 respectively) Conclusion: In patients with MS, the reduction in venous sinus compliance is associated with venous outflow stenoses in the transverse sinuses which increases the upstream venous pressure and dilates the sagittal sinuses. This finding suggests a continuum exists between MS and idiopathic intracranial hypertension.]]> Thu 24 Mar 2022 11:30:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55164 Thu 18 Apr 2024 10:52:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54817 Thu 14 Mar 2024 14:45:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50194 Thu 06 Jul 2023 15:51:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52243 g). Results: Twenty-eight studies met inclusion criteria. Twenty-three of these were randomised controlled trials, with 1246 total participants. This review reports on this data, with non-randomised study data reported in supplemental material. Post -intervention relaxation was associated with medium to large effect-size improvement for depression, anxiety, stress and fatigue. The effects of relaxation were superior to wait-list or no treatment control conditions; however, comparisons with established psychological or physical therapies were mixed. Individual studies reported sustained effects (≤ 6 months) with relaxation for stress, pain and quality of life. Most studies were rated as having a high/serious risk of bias. Conclusion: There is emerging evidence that relaxation therapies can improve outcomes for persons with multiple sclerosis. Given the high risk of bias found for included studies, stronger conclusions cannot be drawn.]]> Thu 05 Oct 2023 14:01:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42680 Thu 01 Sep 2022 08:38:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49695 Mon 29 May 2023 12:46:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38628 + T cells of relapsing–remitting (RR) MS patients compared to healthy controls and identified differentially methylated regions (DMRs) in HLA-DRB1 and RNF39. This study aimed to investigate the DNA methylation profiles of the CD4⁺ T cells of progressive MS patients. DNA methylation was measured in two separate case/control cohorts using the Illumina 450K/EPIC arrays and data was analysed with the Chip Analysis Methylation Pipeline (ChAMP). Single nucleotide polymorphisms (SNPs) were assessed using the Illumina Human OmniExpress24 arrays and analysed using PLINK. Expression was assessed using the Illumina HT12 array and analysed in R using a combination of Limma and Illuminaio. We identified three DMRs at HTR2A, SLC17A9 and HDAC4 that were consistent across both cohorts. The DMR at HTR2A is located within the bounds of a haplotype block; however, the DMR remained significant after accounting for SNPs in the region. No expression changes were detected in any DMRs. HTR2A is differentially methylated in progressive MS independent of genotype. This differential methylation is not evident in RRMS, making it a potential biomarker of progressive disease.]]> Mon 29 Jan 2024 17:52:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48109 Mon 27 Feb 2023 15:22:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48108 Mon 27 Feb 2023 15:18:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51965 Mon 25 Sep 2023 08:53:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42377 Mon 22 Aug 2022 14:29:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53246 Mon 20 Nov 2023 10:14:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43429 P ≤ .05). Only GPC showed positive correlation with all fatigue domains (r = .537, P ≤ .05). On the other hand, Glx-upper, NAA-2, GSH+Hca, and fucose-3 showed negative correlations with all fatigue domains (r = –.345 to –.580, P ≤ .05). While tyrosine showed positive correlation with MFIS (r = .499, P ≤ .05), cognitive fatigue was negatively correlated with total GSH (r = –.530, P ≤ .05). No correlations were found between lesion load or brain volumes with fatigue score. CONCLUSIONS: Our results suggest that fatigue in MS is strongly correlated with an imbalance in neurometabolites but not structural brain measurements.]]> Mon 19 Sep 2022 09:29:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51774 Mon 18 Sep 2023 14:29:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:37094 Mon 17 Aug 2020 12:34:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46218 Mon 14 Nov 2022 12:12:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46199 Mon 14 Nov 2022 11:22:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54196 Mon 12 Feb 2024 14:43:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54178 Mon 12 Feb 2024 13:11:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54767 Mon 11 Mar 2024 15:00:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54737 90 % accuracy in this cohort (AUC=0.92, SE=0.86 - 0.94). Conclusion: Multi-modal MRI signatures can predict cognitive decline in a cohort of pwMS over 5 years with high accuracy. Future studies will benefit from the inclusion of even more MR modalities e.g., functional MRI, quantitative susceptibility mapping, magnetisation transfer imaging, as well as other potential predictors e.g., genetic and environmental factors. With further validation, this signature could be used in future trials with high-risk patients to personalise the management of cognitive decline in pwMS, even in the absence of relapses.]]> Mon 11 Mar 2024 14:19:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39532 Mon 08 Aug 2022 11:20:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42843 n = 195; untreated n = 338). Median on-study pairwise-censored follow-up was 3.4 years (quartiles 1.2–5.5). No difference in the hazard of experiencing 3-month confirmed EDSS progression events was observed between the groups [hazard ratio (HR), 1.0; 95% confidence interval (CI), 0.6–1.7, P = 0.87]. We did not find significant differences in the hazards of confirmed EDSS improvement (HR, 1.0; 95% CI, 0.6–1.6, P = 0.91) or reaching a confirmed EDSS step ≥7 (HR, 1.1; 95% CI, 0.7–1.6, P = 0.69). Conclusion: Our pooled analysis of disease-modifying agents suggests that these therapies have no substantial effect on short- to medium-term disability outcomes in PPMS.]]> Mon 05 Sep 2022 14:44:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54090 Mon 05 Feb 2024 09:20:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46553 Fri 25 Nov 2022 11:33:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:48646 Fri 24 Mar 2023 13:51:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54950 Fri 22 Mar 2024 15:28:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54939 Fri 22 Mar 2024 14:38:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54938 Fri 22 Mar 2024 14:32:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:41083 Fri 22 Jul 2022 17:11:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53845 .1). Conclusion: We found evidence of loss of GM and TBV over time in pwMOGAD, similar to pwMS, although the WM and lesion volumes were unchanged.]]> Fri 19 Jan 2024 10:18:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42294 Fri 19 Aug 2022 14:58:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53050 Fri 17 Nov 2023 12:07:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53044 Fri 17 Nov 2023 11:47:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:55343 Fri 17 May 2024 15:51:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44478 Fri 14 Oct 2022 08:50:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:56392 Fri 13 Sep 2024 14:32:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46091 Fri 11 Nov 2022 09:31:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39508 Fri 10 Jun 2022 15:14:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51498 Fri 08 Sep 2023 11:55:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54685 Fri 08 Mar 2024 11:52:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49201 Fri 05 May 2023 15:58:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49119 Fri 05 May 2023 11:46:07 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49799 Fri 02 Jun 2023 17:06:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>